Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment
|
|
- Morgan Norton
- 5 years ago
- Views:
Transcription
1 Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment
2 Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment Edited by Keith D. Lindor Professor of Medicine MayoClinic 200 First Street SW Rochester; MN E. Jenny Heathcote Professor of Medicine University of Toronto The Toronto Hospital, Westem Division 399 Bathurst Street, Wing Toronto, ONT M5T 2S8 Canada RaoulPoupon Professor of Medicine SeNice d'hepatologie et Gastroenterologie AP - H6pital Saint-Antoine 184, rue Du Faubourg, Saint-Antoine Paris France The proceedings of a symposium organised by AXCAN PHARMA, held in Chicago, November 6, I~I.., ~ SPRINGER SCIENCE+BUSINESS MEDIA, B.V.
3 Library of Congress Cataloging-in-Publication Dala A C.I.P. Catalogue record for this book is available from the Library of Congress. ISBN ISBN (ebook) DOI / Printecl on adcljrel! paper All Rights Reserved 1998 Springer Science+Business Media Dordrecht Original1y published by K1uwer Academic Publishers in 1998 Softcover reprint of the hardcover 1 st edition 1998 No part of this publication may be reproduced or utilized in any form or by any means, electronic, mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner.
4 Contents Scientific Organizers List of Principal Authors Preface Sheila Sherlock vii ix xiii Section I: NATURAL HISTORY AND PATHOGENESIS Natural history and demography of primary biliary cirrhosis 0. F. W. James 3 2 Immune basis for PBC M. F. Bassendine 11 3 Isolation and cloning of anti mitochondrial antibodies R. Joplin 19 4 Significance of anti mitochondrial antibody profiles in primary biliary cirrhosis R. Klein, P. A. Berg 24 5 Chloride/bicarbonate exchange in PBC: a clue for pathogenesis? J. F. Medina, J. Prieto 35 6 Molecular considerations of primary biliary cirrhosis M. E. Gershwin, C. T. Migliaccio, J. Van de Water; R. L. Coppel 40 7 Animal models of primary biliary cirrhosis C. D. Howell, J. U, W. Chen 53 8 Fibrogenesis in PBC D. Schuppan, E. G. Hahn 64 v
5 CONTENTS 9 Natural history models of primary biliary cirrhosis W R. Kim, E. R. Dickson 76 Section II: MANAGEMENT OF PRIMARY BILIARY CIRRHOSIS 10 Portal hypertension in patients with primary biliary cirrhosis P. M. Huet, J. Huet, J. Deslauriers Management of primary biliary cirrhosis: osteoporosis A. Pares Fatigue in the primary biliary cirrhosis patient M. G. Swain The pruritus of cholestasis: behavioral studies shed light on its pathogenesis N. V. Bergasa, E. A. Jones Old and new immunosuppressant drugs: mechanisms and potential value J. M. Vierling Methotrexate and colchicine in the treatment of primary biliary cirrhosis M. M. Kaplan Corticosteroids in PBC H. R. van Buuren Ursodeoxycholic acid treatment of primary biliary cirrhosis: potential mechanisms of action G. Paumgartner Ursodiol and combination therapy R. L. Carithers Jr Primary biliary cirrhosis transplantation and recurrent disease J. Neuberger New clinical trials in primary biliary cirrhosis: design and endpoints J. Everhart 163 Index 173 vi
6 Scientific Organizers KEITH D. LlNDOR Professor of Medicine Mayo Clinic 200 First Street SW Rochester, MN E. JENNY HEATHCOTE Professor of Medicine University of Toronto Chief, Division of Gastroenterology The Toronto Hospital, Western Division 399 Bathurst Street, Wing Toronto, ONT M5T 288 Canada RAOUL POUPON Professor of Hepatology and Gastroenterology Department of Pathology AP - Hopital Saint -Antoine 184, rue Du Faubourg Paris France vii
7 List of Principal Authors M. F. BASSENDINE Uver Unit Freeman Hospital Newcastle upon Tyne NE77DN UK N.V.BERGASA Division of Gastroenterology & Uver Disease Beth Israel Medical Center First Avenue at 16th Street New York NY R. L. CARITHERS Jr. Hepatology Section University of Washington 1959 NE Pacific Street Seattle WA E. R. DICKSON Division of Gastroenterology and Hepatology Mayo Clinic r-n19) 200 First Street SW Rochester MN J.EVERHART Epidemiology and Clinical Trials Branch Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 6AN-12J 45 Center Dr MSC 6600 Bethesda MD ix
8 LIST OF PRINCIPAL AUTHORS M. E. GERSHWIN University of california at Davis Division of Rheumatology, Allergy and Clinical Immunology One Shields Avenue, TB 192, School of Medicine Davis CA C. D. HOWELL Hepatology Section The University of Maryland School of Medicine 22 S Green St Room N3W 130 Baltimore MD P.-M. HUET Hepatology Research Group CHUM Clinical Research Center Sainl-Luc Pavilion 164 Rene-Levesque Blvd. E. Montreal QC H2X 1P1 Canada O. F. W. JAMES School of Clinical Medical Sciences University of Newcastle Senior Consultant Physician Uver Unit Freeman Hospital Newcastle upon Tyne NE24HH UK R. JOPLIN Uver Research Laboratories University Hospital The Queen Elizabeth Hospital Birmingham B152TH UK M. M. KAPLAN Tufts University School of Medicine Gastroenterology Division New England Medical Center 750 Washington Street, Box 233 Boston MA02111 x
9 LIST OF PRINCIPAL AUTHORS R. KLEIN Department of Internal Medicine University of TLibingen Otfried MOiler Str TLibingen Germany J.NEUBERGER The Liver Unit and Hepatobiliary Unit The Queen Elizabeth Hospital Birmingham B152TN UK A.PARES Liver Unit Hospital Clinic i Provincial Calle Villarroel Barcelona Spain G. PAUMGARTNER Department of Medicine II Klinikum Grosshadern Marchioninistrasse 15 D Munich Germany J. PRIETO Department of Medicine and Liver Unit CHnica Universitaria de Navarra Avenida Pio XII. 36 E Pamplona Spain D.SCHUPPAN Department of Medicine I (Gastroenterology & Hepatology) University of Erlangen-NOrnberg Krankenhausstr. 12 D Erlangen Germany M. G. SWAIN Liver Unit. Gastroenterology Research Group Health Sciences Center University of Calgary 3330 Hospital Drive NW Calgary AB T2N 4N1 Canada xi
10 LIST OF PRINCIPAL AUTHORS H. R. VAN BUUREN Department of Hepatogastroenterology and Intemal Medicine University Hospital Rotterdam Dr Molewaterplein GD Rotterdam The Netherlands J. M. VIERLING Center for Uver Diseases and Transplantation 8635 West Third Street, Site 590W Los Angeles CA xii
11 Preface The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptomfree patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect. PBC is generally considered to be an autoimmune disease. The sufferer is believed to be genetically predisposed. There is a weak association with MHC class II allele HLA DR8. The link is however not nearly so close as that found with autoimmune chronic active hepatitis. The part played by mitochondrial antibodies (AMA) in pathogenesis remains controversial. The mitochondrial antigen responsible for the AMA is the pyruvate dehydrogenase complex (PDC). In PBC, aberrant expression of the E2 component of PDC has been shown on bile duct epithelium, possibly rendering bile ducts susceptible to immune-mediated damage. Alternatively, the disease may have an infectious etiology as there is crossreactivity between AMA and sub-cellular constituents of Gram-positive and xiii
12 PRIMARY BILIARY CIRRHOSIS Gram-negative organisms. The AMA found in PBC may be primarily directed against enterobacterial antigens resulting from intestinal infection. The immunological lesion is mediated by CD4 T-cells secreting T-helper cytokines (IL-2, IFNy, TNFoc/IJ). Later, as the bile ducts disappear, fibrosis and cirrhosis develop. Cholestasis is enhanced by decreased levels of biliary transport proteins secondary to the biliary obstruction and to endotoxaemia. Therapy can be directed against any of these injurious processes. Immunological manipulations have been many. Corticosteroids block CD4 lymphocytes but bone thinning prevents their long-term use. Azathioprine, chlorambucil, D-penicillamine and cyclosporin have been tested and generally found wanting, usually because of side-effects or failure to prove benefit in long-term placebo-controlled clinical trials. It is also difficult to justify the continued use, over many years, of drugs which have potential toxicity. Drug failures may also be related to the stage of the disease. It is clearly not possible to reverse cirrhotic nodules and fibrosis or the interference with hepatobiliary transport. Colchicine, which has anti-inflammatory and anti-fibrotic actions, failed to provide conclusive benefit. Methotrexate may benefit some patients in the early stages of PBC but pneumonitis and hematological complications can develop. Ursodeoxycholic acid (UDCA; ursodiol) is currently the most effective medical therapy for PBC. Biochemical tests improve, progression of portal hypertension is reduced and time to death or liver transplantation is prolonged. However, histological changes in the liver progress and effects on lethargy and pruritus are variable. UDCA should be given to all symptomatic patients. The role in pre- and asymptomatic sufferers is not clear. The mechanism of action of UDCA is complex. The bile acid pool becomes more hydrophilic and less detergent so acting as a protectant of the luminal membrane of the interlobular bile ducts. U DCA stimulates the biliary excretion of endogenous hydrophobic (toxic) bile acids, perhaps by stimulating vesicular exocytosis by which transport carrier proteins are targeted to the canalicular membrane. Finally, UDCA may reduce the immune attack of cytotoxic T -cells by decreasing H LA 1 expression on bile ducts. Combinations of drugs may have greater benefit than mono therapy. UDCA plus methotrexate or corticosteroids is being assessed. Triple therapy with prednisolone, azathioprine and UDCA are under trial and results are awaited. Fibrosis accompanies bile ductular proliferation and is responsible for the end picture of cirrhosis. Fibrosis is unaffected by immunomodulation or UDCA and holds the key to reversibility. This has led to therapy with such drugs as colchicine, silimarin and pentoxifyliin, which are largely ineffective. Better anti-fibrotic agents are awaited. Complications such as ascites and portal hypertension need to be treated. Bone thinning may be reduced by etidronate and fluoride. Opiate antagonists are being used to control pruritus. Hepatic transplantation performed before the terminal stages offers a fiveyear survival exceeding 85%. There is increasing evidence of recurrence in the graft. Granulomatous cholangitis develops in the livers of patients having a transplant for PBC but not where the operation is done for other indicxiv
13 PREFACE ations. Short- and medium-term significance of the recurrence is probably little but longer follow-up is necessary. The conference demonstrated the advantages of attracting international experts from various disciplines, clinical, immunological, biochemical, genetic and histopathological, to focus down on one disease. PBC, however, has something for everyone. It provides examples of model situations which can be applied to all of hepatology and indeed to all of general medicine. Sheila Sherlock Department of Surgery Royal Free Hospital London xv
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationClinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis
Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis ANNE-MARIE BONNAND, 1 E. JENNY HEATHCOTE, 2 KEITH D. LINDOR, 3 AND RENÉE EUGÉNIE
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationCLINICAL GASTROENTEROLOGY
CLINICAL GASTROENTEROLOGY Series Editor George Y. Wu University of Connecticut Health Center, Farmington, CT, USA For further volumes: http://www.springer.com/series/7672 Elizabeth J. Carey Keith D. Lindor
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationImmunology for the Practicing Physician
Immunology for the Practicing Physician Immunology for the Practicing Physician Edited by Jon R. Schmidtke and Ronald M. Ferguson Departments of Surgery and Microbiology University of Minnesota Medical
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationCopper and Zinc in Inflammatory and Degenerative Diseases
Copper and Zinc in Inflammatory and Degenerative Diseases Copper and Zinc in Inflammatory and Degenerative Diseases Edited by K.O. Rainsford Division of Biomedical Sciences, School of Science and Mathematics,
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPSYCHIATRIC CONSEQUENCES OF BRAIN DISEASE IN THE ELDERLY. A Focus on MANAGEMENT
PSYCHIATRIC CONSEQUENCES OF BRAIN DISEASE IN THE ELDERLY A Focus on MANAGEMENT PSYCHIATRIC CONSEQUENCES OF BRAIN DISEASE IN THE ELDERLY A Focus on MANAGEMENT Edited by David K. Conn Bayerest Centre for
More informationUrsodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis
T h e n e w e ng l a nd j o u r na l o f m e dic i n e clinical therapeutics Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis Keith Lindor, M.D. This Journal feature begins with a case
More informationThyroid Ultrasound and Ultrasound-Guided FNABiopsy
Thyroid Ultrasound and Ultrasound-Guided FNABiopsy Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy edited by H. Jack Baskin, M.D. Florida Thyroid and Endocrine Clinic Orlando, Florida, USA Springer-Science+Business
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationR ecent estimates suggest that there are
865 LIVER Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort M I Prince, A Chetwynd, W L Craig, J V Metcalf, O F W James...
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationRANDOMISED CONTROLLED CLINICAL TRIALS, Second Edition
RANDOMISED CONTROLLED CLINICAL TRIALS, Second Edition RANDOMISED CONTROLLED CLINICAL TRIALS, Second Edition Christopher J Bulpitt Division of Geriatric Medicine Royal Postgraduate Medical School Hammersmith
More informationOFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE
CLUSTER HEADACHE OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE CLUSTER HEADACHE EDITED BY NINAN 1. MATHEW, M.D. DIRECTOR, HOUSTON HEADACHE CLINIC AND DEPARTMENT OF NEUROLOGY
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationGEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationURSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS URSODIOL FOR PRIMARY SCLEROSING CHOLANGITIS. Patients
KEITH D. LINDOR, M.D., FOR THE MAYO PRIMARY SCLEROSING CHOLANGITIS URSODEOXYCHOLIC ACID STUDY GROUP* ABSTRACT Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis.
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationANALYZING T CELL RESPONSES
ANALYZING T CELL RESPONSES How to Analyze Cellular Immune Responses Analyzing T Cell Responses against Tumor Associated Antigens Edited by DIRK NAGORSEN Charité University Medicine Berlin, Berlin, Germany
More informationPrinciples of Renal Physiology. 4th Edition
Principles of Renal Physiology 4th Edition Principles of Renal Physiology 4th Edition Chris Lote Professor of Experimental Nephrology, University of Birmingham, UK SPRINGER SCIENCE+BUSINESS MEDIA, B.V.
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationPrevention of Skin Cancer
Prevention of Skin Cancer Cancer Prevention Cancer Causes Volume 3 Prevention of Skin Cancer Edited by David Hill, Ph.D. Centre for Behavioural Research in Cancer, The Cancer Council Victoria, Melbourne,
More informationAtlas of Rheumatoid Arthritis
Atlas of Rheumatoid Arthritis Atlas of Rheumatoid Arthritis Professor Paul Emery, Editor Published by Springer Healthcare Ltd, 236 Gray s Inn Road, London, WC1X 8HB, UK. www.springerhealthcare.com 2015
More informationTHE CHEMISTRY OF TOBACCO AND TOBACCO SMOKE
THE CHEMISTRY OF TOBACCO AND TOBACCO SMOKE THE CHEMISTRY OF TOBACCO AND TOBACCO SMOKE Proceedings of the Symposium on the Chemical Composition of Tobacco and Tobacco Smoke held during the 162nd National
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationLEGAL ASPECTS OF ANAESTHESIA
LEGAL ASPECTS OF ANAESTHESIA DEVELOPMENTS IN CRITICAL CARE MEDICINE AND ANESTHESIOLOGY Volume 21 For a list of the volumes in this series see final page of the volume. LEGAL ASPECTS OF ANAESTHESIA edited
More informationMedical and Surgical Complications of Sickle Cell Anemia
Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Department of Surgery Dar A lalafia Medical Company Qatif
More informationValue of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA
More informationFIBER DEFICIENCY AND COLONIC DISORDERS
FIBER DEFICIENCY AND COLONIC DISORDERS FIBER DEFICIENCY AND COLONIC DISORDERS Edited by Richard W. Reilly and Joseph B. Kirsne.r Department of Medicine The Pritzker School of Medicine The University of
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationCOMMON BILE DUCT EXPLORATION
COMMON BILE DUCT EXPLORATION DEVELOPMENTS IN SURGERY J.M. Greep, H.A.J. Lemmens, D.B. Roos, H.C. Urschel, eds., Pain in Shoulder and Arm: An Integrated View ISBN 90 247 2146 6 B. Niederle, Surgery of the
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationHepatitis C Virus and Liver Transplantation
Hepatitis C Virus and Liver Transplantation Marina Berenguer Editor Hepatitis C Virus and Liver Transplantation 2123 Editor Marina Berenguer, MD Department of Hepatology and Liver Transplantation La Fe
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationHepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationPrimary biliary cirrhosis (PBC) is a rare chronic inflammatory CLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2005;128:297 303 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT The Effect of Ursodeoxycholic Acid Therapy on the Natural Course of Primary Biliary Cirrhosis CHRISTOPHE CORPECHOT,* FABRICE
More informationVasilis Vasiliou. Q. Max Guo. Alcohol and Cancer
Alcohol and Cancer Samir Zakhari Editors Vasilis Vasiliou Q. Max Guo Alcohol and Cancer Editors Samir Zakhari, Ph.D. Director Division of Metabolism and Health Effects National Institute on Alcohol Abuse
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationCanine Chronic Idiopathic Hepatitis
Canine Chronic Idiopathic Hepatitis David C. Twedt DVM, DACVIM Problem Acute Rt rear leg lameness History Probably stepped on by owner s horse Healthy otherwise No medications Physical exam Possible partial
More informationTALKING POINTS IN DERMATOLOGY -III
TALKING POINTS IN DERMATOLOGY -III Other titles in the New Clinical Applications Series: Dermatology (Series Editor Dr J. L. Verbov) Dermatological Surgery Superficial Fungal Infections Talking Points
More informationPrimary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between
Primary Biliary Cirrhosis at Hospital Kuala Lumpur: A Study of 11 Cases Seen Between 1992 and 1999 R Kananathan, MRCPI, R L Suresh, MRCP, I Merican, FRCP, Department of Medicine, Hospital Kuala Lumpur,
More informationPrimary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom?
Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom? OLIVER F. W. J AMES, 1 RAJ BHOPAL, 2 DENISE HOWEL, 2 JACKIE GRAY, 2 ALASTAIR D. BURT, 1 AND JANE V. METCALF 1 There is a widespread
More informationResident, PGY1 David Geffen School of Medicine at UCLA. Los Angeles Society of Pathology Resident and Fellow Symposium 2013
Resident, PGY1 David Geffen School of Medicine at UCLA Los Angeles Society of Pathology Resident and Fellow Symposium 2013 85 year old female with past medical history including paroxysmal atrial fibrillation,
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationTOPICS IN DIETARY FIBER RESEARCH
TOPICS IN DIETARY FIBER RESEARCH TOPICS IN DIETARY FIBER RESEARCH Edited by Gene A. Spiller Syntex Research Palo Alto, California With the assistance of Ronald J. Amen Syntex Research Palo Alto, California
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationRheumatoid Arthritis and Proteus
Rheumatoid Arthritis and Proteus Alan Ebringer Rheumatoid Arthritis and Proteus Alan Ebringer B.Sc., M.D., FRCP, FRACP, FRCPath Professor of Immunology King s College London and Honorary Consultant Rheumatologist
More informationSocial Psychology of Self-Referent Behavior
Social Psychology of Self-Referent Behavior Social Psychology of Self-Referent Behavior Howard B. Kaplan Baylor College of Medicine Houston, Teras Springer Science + Business Media, LLC Library of Congress
More informationHistometric and Serial Section Observations of the Intrahepatic Bile Ducts in Primary Biliary Cirrhosis
GASTROENTEROLOGY 761326-1332, 1979 Histometric and Serial Section Observations of the Intrahepatic Bile Ducts in Primary Biliary Cirrhosis YASUNI NAKANUMA and GOROKU OHTA Second Department of Pathology,
More informationPulmonary Manifestations of Rheumatic Disease
Pulmonary Manifestations of Rheumatic Disease Paul F. Dellaripa Aryeh Fischer Kevin R. Flaherty Editors Pulmonary Manifestations of Rheumatic Disease A Comprehensive Guide With 64 Figures, 26 in Color
More informationCOPING WITH CANCER STRESS
COPING WITH CANCER STRESS COPING WITH CANCER STRESS edited by BASIL A. STOLL Honorary consultant physicion to oncology departments St. Thomos' Hospital and Royal Free Hospital London, U.K. Introduction
More informationLong term outcome and response to therapy of primary biliary cirrhosis autoimmune hepatitis overlap syndrome *
Journal of Hepatology 44 (2006) 400 406 www.elsevier.com/locate/jhep Long term outcome and response to therapy of primary biliary cirrhosis autoimmune hepatitis overlap syndrome * Olivier Chazouillères
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationGastrointestinal Motility. Tests and Problem-Oriented Approach
Gastrointestinal Motility Tests and Problem-Oriented Approach Gastrointestinal Motility Tests and Problem-Oriented Approach Edited by University of Iowa College of Medicine Associate Editors Jeffrey L.
More informationFRONTIERS IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILIIT
FRONTIERS IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILIIT This copy is presented as a service to the medical profession by LEE FOUNDATION SINGAPORE DEDICATION This book is dedicated to our wives and families
More informationPancreas and Biliary Disease
Pancreas and Biliary Disease Kulwinder Dua Reza Shaker Editors Pancreas and Biliary Disease A Point of Care Clinical Guide Editors Kulwinder Dua Division of Gastroenterology & Hepatology Medical College
More informationA Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity: A Case Report
doi: 10.2169/internalmedicine.0405-17 Intern Med Advance Publication http://internmed.jp CASE REPORT A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity: A Case
More informationLatest PSC Research. Joseph A Odin, MD, PhD
Latest PSC Research Joseph A Odin, MD, PhD Associate Professor of Medicine Director, New York Autoimmune Liver Disease Programs at Mount Sinai School of Medicine September 8, 2009 Outline Very Quick Overview
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More informationUnderstanding Incontinence
Understanding Incontinence Understanding Incontinence A GUIDE TO THE NATURE AND MANAGEMENT OF A VERY COMMON COMPLAINT Dorothy Mandelstam MCSP DipSocSc With illustrations by Brenda Naylor SPRINGER-SCIENCE+BUSINESS
More informationEvaluation of Clinical Biofeedback
Evaluation of Clinical Biofeedback Evaluation of Clinical Biofeedback William J. Ray, James M. Raczynski, Todd Rogers, and William H. Kimball The Pennsylvania State University University Park, Pennsylvania
More informationThe True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study
GASTROENTEROLOGY 2002;122:1235 1241 The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study JENNIFER GOLDBLATT,* PHILIP J. S. TAYLOR, TOBY LIPMAN, MARTIN I. PRINCE,* ANNA BARAGIOTTA,*
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationUrsodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability
430 Melchor-Mendoza YK, et al., 2017; 16 (3): 430-435 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 430-435 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association
More informationLymphoproliferative Diseases
Lymphoproliferative Diseases IMMUNOLOGY AND MEDICINE SERIES Immunology of Endocrine Diseases Editor: A. M. McGregor Clinical Transplantation: Current Practice and Future Prospects Editor: G. R. D. Catto
More informationBioavailability and Analysis of Vitamins in Foods
Bioavailability and Analysis of Vitamins in Foods JOIN US ON THE INTERNET VIA WWW, GOPHER, FTP OR EMAIL: WWW: http://www.thomson.com GOPHER: gopher.thomson.com FTP: ftp.thomson.com EMAIL: findit@kiosk.thomson.com
More information